- Details
- Alicia Morgans interviews Thomas Zilli about the PEACE V study. The study, termed the STORM trial, investigates treatment strategies for patients with oligorecurrent prostate cancer, comparing focalized SBRT, comprehensive irradiation, and salvage lymph node dissection combined with six months of ADT. Aimed at determining the best approach for these patients, the trial specifically looks at metast...
|
- Details
- Zach Klaassen discusses his lecture on the topic of testicular cancer and survivorship during a discussion with Alicia Morgans. Highlighting the long-term effects of chemotherapy, Dr. Klaassen emphasizes the profound impact on young patients who often live decades post-diagnosis. His presentation addresses the serious long-term toxicities, noting that one in five survivors experiences significant...
|
- Details
- Irene Burger discusses the significant impact of PSMA PET in diagnosing high-risk localized prostate cancer. Dr. Burger describes the rapid adoption of this technology in Switzerland, emphasizing its enhanced sensitivity over traditional imaging since its integration in 2016. Dr. Burger highlights the broad acceptance and crucial insights from significant studies, such as the proPSMA trial, which...
|
- Details
- Cora Sternberg discusses the significant advancement in the treatment of urothelial carcinoma, focusing on enfortumab vedotin (EV) in combination with pembrolizumab. This combination, recently approved in the US as a first-line therapy, has shifted the treatment paradigm, offering a potent alternative to traditional platinum-based therapies. Dr. Sternberg highlights the importance of this developm...
|
- Details
- Alicia Morgans speaks with Bertrand Tombal about his presentation at EAU 2024, focusing on the European subset of the ARASENS trial. Professor Tombal discusses the importance of the data from this trial, which assessed the efficacy of adding darolutamide to standard treatment for metastatic hormone-naive prostate cancer. The trial confirmed that this combination significantly reduced mortality ris...
|
- Details
- Alicia Morgans and Alberto Bossi discuss the integration of local prostate treatment in metastatic hormone-sensitive prostate cancer, focusing on findings from the PEACE-1 trial and related studies. Professor Bossi highlights the challenge in identifying patients who could benefit most from local radiotherapy, especially given the evolution in imaging technologies like PSMA PET, which may redefine...
|
- Details
- Alicia Morgans discusses the evolving strategies for treating metastatic hormone-sensitive prostate cancer (mHSPC) with Karim Fizazi. Professor Fizazi critiques the traditional method of classifying metastatic disease by the volume of metastases, advocating for a more nuanced approach. He highlights recent phase three trials that suggest a shift away from simply categorizing disease into low and h...
|
- Details
- Alicia Morgans hosts Shankar Siva who sheds light on the innovative use of Stereotactic Ablative Body Radiotherapy (SBRT/SABR) for treating oligometastatic kidney cancer. Dr. Siva outlines the three clinical scenarios where SABR is employed: de novo oligometastatic disease, oligoprogressive disease during systemic therapy, and in certain de novo metastatic settings. He emphasizes the effectiveness...
|
